Recursion Pharmaceuticals (NASDAQ: RXRX) could be one of them. Let's figure out whether investing in Recursion Pharmaceuticals ahead of 2025 is worth it...
Category - 3rdPartyFeeds
Last week, space news site Payload Space told the heartwarming tale of a small Ukrainian company, "Promin," and its quixotic quest to build a new rocket by...
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even... Read More...
Morgan Stanley says the firm has “tended to be most enthusiastic” on Nvidia (NVDA) when “near-term data points appear mixed, but underlying dynamics are very...
It's not a secret: The cannabis industry has been a major disappointment since Canada legalized recreational use in 2018. Tilray's CEO, Irwin Simon, recently...
Palantir (NASDAQ: PLTR) has quickly emerged as a top artificial intelligence (AI) stock pick for many investors. Palantir makes AI software for its clients...
Low-end legacy chips not subject to restrictions but vital to industry have given strength to Chinese manufacturers. Read More...
Investors should think of artificial intelligence (AI) in three phases. The second phase involves cloud providers that offer infrastructure and platform...
A wave of AI uncertainty and valuation concerns have stopped this highflier in its tracks, but blistering gains could be on the horizon. Read More...
Nvidia (NASDAQ: NVDA) is the top player in the market for data center graphics processing units (GPUs) that are being deployed in data centers for artificial...
